Barclays Cuts Agilent Technologies (A) Price Target to $86.00

Share on StockTwits

Agilent Technologies (NYSE:A) had its target price reduced by investment analysts at Barclays from $88.00 to $86.00 in a research note issued to investors on Wednesday, BenzingaRatingsTable reports. The brokerage currently has an “overweight” rating on the medical research company’s stock. Barclays‘s price objective would indicate a potential upside of 24.33% from the company’s current price.

A has been the subject of a number of other research reports. Bank of America reiterated a “buy” rating and issued a $87.00 price objective (up previously from $78.00) on shares of Agilent Technologies in a research report on Thursday, February 21st. UBS Group initiated coverage on Agilent Technologies in a research report on Friday, March 15th. They set a “buy” rating and a $92.00 target price for the company. Cowen raised their target price on Agilent Technologies from $80.00 to $90.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 26th. JPMorgan Chase & Co. raised their target price on Agilent Technologies to $85.00 and gave the stock an “overweight” rating in a research report on Thursday, February 21st. Finally, Janney Montgomery Scott restated a “buy” rating and set a $90.00 target price (up previously from $80.00) on shares of Agilent Technologies in a research report on Thursday, February 21st. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Agilent Technologies currently has an average rating of “Buy” and an average price target of $86.58.

Shares of NYSE:A opened at $69.17 on Wednesday. Agilent Technologies has a twelve month low of $60.42 and a twelve month high of $82.27. The company has a market cap of $21.48 billion, a P/E ratio of 24.79, a price-to-earnings-growth ratio of 1.88 and a beta of 1.33. The company has a quick ratio of 2.79, a current ratio of 3.41 and a debt-to-equity ratio of 0.35.

Agilent Technologies (NYSE:A) last announced its earnings results on Tuesday, May 14th. The medical research company reported $0.71 earnings per share for the quarter, missing the consensus estimate of $0.72 by ($0.01). Agilent Technologies had a net margin of 22.25% and a return on equity of 19.71%. The business had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.27 billion. During the same quarter in the previous year, the company earned $0.65 EPS. Agilent Technologies’s revenue for the quarter was up 2.7% compared to the same quarter last year. On average, equities research analysts forecast that Agilent Technologies will post 3.06 earnings per share for the current fiscal year.

In related news, VP Rodney Gonsalves sold 6,155 shares of the firm’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $79.79, for a total transaction of $491,107.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Mark Doak sold 16,421 shares of the firm’s stock in a transaction on Friday, February 22nd. The shares were sold at an average price of $77.95, for a total value of $1,280,016.95. The disclosure for this sale can be found here. Insiders have sold a total of 48,583 shares of company stock valued at $3,855,924 over the last ninety days.

A number of hedge funds have recently added to or reduced their stakes in A. Parallel Advisors LLC boosted its position in shares of Agilent Technologies by 3.9% in the 4th quarter. Parallel Advisors LLC now owns 4,002 shares of the medical research company’s stock worth $269,000 after purchasing an additional 149 shares during the last quarter. Fruth Investment Management boosted its position in shares of Agilent Technologies by 0.3% in the 4th quarter. Fruth Investment Management now owns 45,351 shares of the medical research company’s stock worth $3,059,000 after purchasing an additional 150 shares during the last quarter. BOKF NA boosted its position in shares of Agilent Technologies by 1.4% in the 4th quarter. BOKF NA now owns 11,229 shares of the medical research company’s stock worth $757,000 after purchasing an additional 158 shares during the last quarter. Sumitomo Life Insurance Co. boosted its position in shares of Agilent Technologies by 1.3% in the 4th quarter. Sumitomo Life Insurance Co. now owns 13,394 shares of the medical research company’s stock worth $904,000 after purchasing an additional 178 shares during the last quarter. Finally, Mission Wealth Management LP boosted its position in shares of Agilent Technologies by 2.1% in the 4th quarter. Mission Wealth Management LP now owns 8,629 shares of the medical research company’s stock worth $582,000 after purchasing an additional 179 shares during the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

Further Reading: Institutional Investors

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.